Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-26T03:48:33.344Z Has data issue: false hasContentIssue false
  • English
  • Français

Assessment of Relapse in Patients with Schizophrenia during COVID-19 pandemic

Published online by Cambridge University Press:  01 September 2022

E. Abdelfattah ,
M. Bassiony ,
M. Sehlo ,
A. Zayed  and
S. Atwa
E. Abdelfattah*
Affiliation:
Faculty of medicine, Zagazig University, Psychiatry, Zagazig, Egypt
M. Bassiony
Affiliation:
Faculty of medicine, Zagazig University, Psychiatry, Zagazig, Egypt Faculty of medicine Zagazig university, Psychiatry, Zagazig, Egypt
M. Sehlo
Affiliation:
Faculty of medicine, Zagazig University, Psychiatry, Zagazig, Egypt
A. Zayed
Affiliation:
Faculty of medicine, Zagazig University, Psychiatry, Zagazig, Egypt
S. Atwa
Affiliation:
Faculty of medicine, Zagazig University, Psychiatry, Zagazig, Egypt
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

People with schizophrenia could be more substantially influenced by the emotional stress brought on by the COVID-19 pandemic, resulting in relapses or worsening of an already existing mental health condition because of the high susceptibility to stress.

Objectives

This study aimed to assess the presence of relapse and its risk factors among patients with schizophrenia during the era of COVID 19 pandemic.

Methods

This study included 90 adults who met DSM-5 criteria for schizophrenia and were diagnosed by (SCID-I) Arabic version and who are following up at the outpatient psychiatric clinic, Zagazig University Hospital, Egypt, Positive and Negative Syndrome Scale (PANSS) measuring severity of symptoms, Compliance Rating Scale (CRS) and World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0). scales were conducted on those patients before COVID-19 pandemic from January to April 2019 and repeated on September to November 2020 during COVID 19 pandemic to compare clinical parameters between those two periods as to detect any deterioration in their clinical state.

Results

The mean score of compliance rating scale (CRS) was decreased after COVID-19 pandemic compared to before COVID 19 (P<0.001).The mean score of PANSS scale positive subscale (P) had increased after COVID-19 pandemic compared to before COVID 19 (P<0.001).

Conclusions

There was a deterioration of the clinical state of schizophrenic patients during COVID-19 pandemic especially the positive symptoms and following up the news about COVID-19 regularly, decreased level of family support, lower level of compliance with treatment, and having a family member with COVID-19 infection or death were the risk factors for relapse.

Disclosure

No significant relationships.

Keywords

complianceCovid-19Relapseschizophrénia
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S309 - S310
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.